Hostname: page-component-848d4c4894-cjp7w Total loading time: 0 Render date: 2024-06-20T12:39:57.389Z Has data issue: false hasContentIssue false
  • English
  • Français

The Potential Role of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Psychiatric Disorders

Published online by Cambridge University Press:  07 November 2014

Stephen M. Stahl  and
Dana D. Wise
Get access Rights & Permissions [Opens in a new window]

Extract

The hypothalamic-pituitary-adrenal axis is a key mediator of the stress response in humans. The corticotropin-releasing factor (CRF) type 1 receptor (CRFR-1) in the pituitary gland is a gatekeeper for that response, and the CRFR-1 receptor is also present in many other mood- and cognition-related neural structures. Behaviorally, a number of relationships between stress and psychiatric disorders can be observed: chronic or repeated stress is associated with onset of depression; stressors can cause a recovering alcoholic to relapse; overactive stress responses mark many anxiety disorders; and insomnia can arise from an overactive stress response. Thus, a CRFR-1 antagonist could be useful for treating or preventing the consequences of CRF-mediated stress in depression, anxiety, insomnia, and substance abuse.

Type
Trends in Psychopharmacology
Information
CNS Spectrums , Volume 13 , Issue 6 , June 2008 , pp. 467 - 483
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Nestler, EJ, Barrot, M, DiLeone, RJ, Eisch, AJ, Gold, SJ, Monteggia, LM. Neurobiology of depression. Neuron. 2002;34:13–25.Google Scholar
2.Sanchez, M, Young, L, Plotsky, P, Insel, T. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol. 1999;408:365–377.3.0.CO;2-N>CrossRefGoogle ScholarPubMed
3.Ohl, F, Michaelis, T, Vollmann-Honsdorf, GK, Kirschbaum, C, Fuchs, E. Effect of chronic psychosocial stress and long-term cortisol treatment on hippocampus-mediated memory and hippocampal volume: a pilot-study in tree shrews. Psychoneuroendocr inology. 2000;25:357–363.Google Scholar
4.Kostich, WA, Grzanna, R, Lu, NZ, Largent, BL. Immunohistochemical visualization of corticotropin-releasing factor type 1 (CRF1) receptors in monkey brain. J Comp Neurol. 2004;478:111–125.CrossRefGoogle ScholarPubMed
5.Oshida, Y, Ikeda, Y, Chaki, S, Okuyama, S. Monkey corticotropin-releasing factor1 receptor: complementary DNA cloning and pharmacological characterization. Life Sci. 2004;74:1911–1924.Google Scholar
6.Rosene, DL, Van Hoesen, GW. The hippocampal formation of the primate brain: a review of some comparative aspects of cytoarchitecture and connections. In: Jones, EG, Peters, A, eds. Cerebral Cortex. Further Aspects of Cortical Function, Including Hippocampus. vol. 6. New York, NY: Plenum Press; 1987;345–456CrossRefGoogle Scholar
7.Radulovic, J, Ruhmann, A, Liepold, T, Spiess, J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci. 1999;19:5016–5025.Google Scholar
8.Santarelli, L, Saxe, M, Gross, C, et al.Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805–809.Google Scholar
9.Frodl, T, Schule, C, Schmitt, G, et al.Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry. 2007;64:410–416.Google Scholar
10.Mullen, PE, Martin, JL, Anderson, JC, Romans, SE, Herbison, GP. The long-term impact of the physical, emotional, and sexual abuse of children: a community study. Child Abuse Negl. 1996;20:7–21.Google Scholar
11.Vythilingam, M, Heim, C, Newport, J, et al.Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry. 2002;159:2072–2080.Google Scholar
12.American Psychiatric Association. Mood episodes: major depressive episode. In: Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000;349–356.Google Scholar
13.Frodl, T, Schaub, A, Banac, S, et al.Reduced hippocampal volume correlates with executive dysfunctioning in major depression. J Psychiatry Neurosci. 2006;31:316–323.Google Scholar
14.Stahl, SM. Mood disorders. In: Stahl's Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008;453–510.Google Scholar
15.Stahl, SM, Zhang, L, Damatarca, C, Grady, M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry. 2003;64(suppl 14):6–17.Google Scholar
16.Fontenot, MB, Kaplan, JR, Manuck, SB, Arango, V, Mann, JJ. Long-term effects of chronic social stress on serotonergic indices in the prefrontal cortex of adult male cynomolgus macaques. Brain Res. 1995;705:105–108.Google Scholar
17.Laaris, N, Hajdahmane, S, Hamon, M, Lanfumey, L. Glucocorticoid receptor-mediated inhibition by corticosterone of 5-HT1A autoreceptor functioning in the rat dorsal raphe nucleus. Neuropharmacology. 1995;34:1201–1210.CrossRefGoogle ScholarPubMed
18.Clark, MS, Russo, AF. Tissue-specific glucocorticoid regulation of tryptophan hydroxylase mRNA levels. Mol Brain Res. 1997;48:346–354.Google Scholar
19.Lukkes, JL, Forster, GL, Renner, KJ, Summers, CH. Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphe differentially affect serotonin release in the nucleus accumbens. Eur J Pharmacol. 2008;578:185–193.Google Scholar
20.Caspi, A, Sugden, K, Moffitt, TE, et al.Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386–389.Google Scholar
21.O'Hara, R, Schroder, CM, Mahadevan, R, et al.Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. Mol Psychiatry. 2007;12:544–555.CrossRefGoogle ScholarPubMed
22.Ihalainen, JA, Riekkinen, P Jr, Feenstra, MG. Comparison of dopamine and noradrenaline release in mouse prefrontal cortex, striatum and hippocampus using microdialysis. Neurosci Lett. 1999;277:71–74.Google Scholar
23.Pacak, K, Palkovits, M, Kvetnansky, R, et al.Catecholaminergic inhibition by hypercortisolemia in the paraventricular nucleus of conscious rats. Endocrinology. 1995;136:4814–4819.Google Scholar
24.Makino, S, Smith, MA, Gold, PW. Regulatory role of glucocorticoids and glucocorticoid receptor mRNA levels on tyrosine hydroxylase gene expression in the locus coeruleus during repeated immobilization stress. Brain Res. 2002;943:216–223.Google Scholar
25.Finlay, JM, Zigmond, MJ. The effects of stress on central dopaminergic neurons: Possible clinical implications. Neurochem Res. 1997;22:1387–1394.Google Scholar
26.Lucas, LR, Celen, Z, Tamashiro, KLK, et al.Repeated exposure to social stress has long-term effects on indirect markers of dopaminergic activity in brain regions associated with motivated behavior. Neuroscience. 2004;124:449–457.Google Scholar
27.Mangiavacchi, S, Masi, F, Scheggi, S, Leggio, B, De Montis, MG, Gambarana, C. Long-term behavioral and neurochemical effects of chronic stress exposure in rats. J Neurochem. 2001;79:1113–1121.Google Scholar
28.Imperato, A, Puglisi-Allegra, S, Casolini, P, Angelucci, L. Changes in brain dopamine and acetylcholine release during and following stress are independent of the pituitary-adrenocortical axis. Brain Res. 1991;538:111–117.Google Scholar
29.Ortiz, J, DeCarpio, JL, Kosten, TA, Nestler, EJ. Strain-selective effects of corticosterone on locomotor sensitization to cocaine and on levels of tyrosine hydroxylase and gluco-corticoid receptor in the ventral tegmental area. Neuroscience. 1995;67:383–397.Google Scholar
30.American Psychiatric Association. Anxiety disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000;429–484.Google Scholar
31.Stahl, SM. Anxiety disorders and anxiolytics. In: Stahl's Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008;721–772.Google Scholar
32.Inoue, T, Li, XB, Abekawa, T, et al.Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdala. Eur J Pharmacol. 2004;497:311–316.Google Scholar
33.Helmstetter, FJ. Stress-induced hypoalgesia and defensive freezing are attenuated by application of diazepam to the amygdala. Pharmacol Biochem Behav. 1993;44:433–438.Google Scholar
34.Heim, C, Nemeroff, CB. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry. 1999;46:1509–1522.CrossRefGoogle ScholarPubMed
35.Amat, J, Tamblyn, JP, Paul, ED, et al.Microinjection of urocortin 2 into the dorsal raphe nucleus activates serotonergic neurons and increases extracellular serotonin in the basolateral amygdala. Neuroscience. 2004;129:509–519.CrossRefGoogle ScholarPubMed
36.Kirby, LG, Rice, KC, Valentino, RJ. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology. 2000;22:148–162.Google Scholar
37.Page, ME, Abercrombie, ED. Discrete local application of corticotropin-releasing factor increases locus coeruleus discharge and extracellular norepinephrine in rat hippocampus. Synapse. 1999;33:304–313.Google Scholar
38.Kawahara, H, Kawahara, Y, Westerink, BH. The role of afferents to the locus coeruleus in the handling stress-induced increase in the release of noradrenaline in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain. Eur J Pharmacol. 2000;387:279–286.Google Scholar
39.Shin, LM, Rauch, S, Pitman, R. Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann NY Acad Sci. 2006;1071:67–79.Google Scholar
40.Kim, J, Gorman, J. The psychobiology of anxiety. Clin Neurosci Res. 2005;4:335–347.Google Scholar
41.Straube, T, Mentzel, HJ, Miltner, WH. Neural mechanisms of automatic and direct processing of phobogenic stimuli in specific phobia. Biol Psychiatry. 2006;59:162–170.Google Scholar
42.McClure, EB, Monk, CS, Nelson, EE, et al.Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. Arch Gen Psychiatry. 2007;64:97–106.Google Scholar
43.Baker, DG, West, SA, Nicholson, WE, et al.Serial CSF corticotropln-releasing hormone levels and adrenocortical activity In combat veterans with posttraumatic stress disorder. Am J Psychiatry. 1999;156:585–588.CrossRefGoogle ScholarPubMed
44.Kling, MA, Debellis, MD, Orourke, DK, et al.Diurnal variation of cerebrospinal-fluid immunoreactive corticotropin-releasing hormone levels in healthy volunteers. J Clin Endocrinol Metab. 1994;79:233–239.Google Scholar
45.Nosek, T, ed. Essentials of Human Physiology. Available at: http://www.lib.mcg.edu/edu/eshuphysio/program/default.htm. Accessed February 19, 2008.Google Scholar
46.Kalen, R, Rosegren, E, Lindvall, O, Bjorklund, A. Hippocampal noradrenaline and serotonin release over 24 hours as measured by the dialysis technique in freely moving rats: correlation to behavioral activity state, effect of handling and tail-pinch. Eur J Neurosci. 1989;1:181–188.Google Scholar
47.O'Neill, RD, Fillenz, M. Simultaneous monitoring of dopamine release In rat frontal cortex, nucleus accumbens and striatum: effect of drugs, circadian changes and correlations with motor activity. Neuroscience. 1985;16:49–55.Google Scholar
48.Stahl, SM. Disorders of sleep and wakefulness and their treatment. In: Stahl's Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008:815–862.Google Scholar
49.Park, SP. In vivo microdlalysis measures of extracellular norepinephrine in the rat amygdala during sleep-wakefulness. J Korean Med Sci. 2002;17:395–399.Google Scholar
50.Roth, T, Roehrs, T, Pies, R. Insomnia: pathophysiology and implications for treatment. Sleep Med Rev. 2007;11:71–79.Google Scholar
51.Gianoulakis, C, Dai, X, Brown, T. Effect of chronic alcohol consumption on the activity of the hypothalamic-pitultary-adrenal axis and pituitary beta-endorphin as a function of alcohol intake, age, and gender. Alcohol Clin Exp Res. 2003;27:410–423.Google Scholar
52.Clarke, TK, Treutlein, J, Zimmermann, US, et al.HPA-axis activity in alcoholism: examples for a gene-environment interaction. Addict Biol. 2008;13:1–14.Google Scholar
53.Hellig, M, Koob, G. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 2007;30:399–406.Google Scholar
54.Funk, CK, Zorrilla, EP, Lee, MJ, Rice, KC, Koob, GF. Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry. 2007;61:78–86.CrossRefGoogle ScholarPubMed
55.Funk, CK, O'Dell, LE, Crawford, EF, Koob, GF. Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci. 2006;26:11324–11332.Google Scholar
56.Fava, M, Rankin, MA, Wright, EC, et al.Anxiety disorders in major depression. Compr Psychiatry. 2000;41:97–102.Google Scholar
57.Bleich, A, Koslowsky, M, Dolev, A, Lerer, B. Post-traumatic stress disorder and depression. An analysis of comorbidity. Br J Psychiatry. 1997;170:479–482.Google Scholar
58.Campbell, DG, Felker, BL, Liu, CF, et al.Prevalence of depresslon-PTSD comorbidity: Implications for clinical practice guidelines and primary care-based interventions. J Gen Intern Med. 2007;22:711–718.Google Scholar
59.Fava, M, Alpert, JE, Carmin, CN, et al.Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder In STAR*D. Psychol Med. 2004;34:1299–1308.Google Scholar
60.MacMillan, S, Szeszko, PR, Moore, GJ, et al.Increased amygdala: hippocampal volume ratios associated with severity of anxiety In pediatric major depression. J Child Adolesc Psychopharmacol. 2003;13:65–73.Google Scholar
61.Fava, M, Mccall, WV, Krystal, A, et al.Eszoplclone co-administered with fluoxetine In patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59:1052–1060.CrossRefGoogle ScholarPubMed
62.Montgomery, S, Kinrys, G, Krystal, A, et al.Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with generalized anxiety disorder and insomnia, Eur Psychiatry. 2007;22(suppl 1):S238–S239.Google Scholar
63.Kessler, RC, Nelson, CB, McGonagle, KA, Edlund, MJ, Frank, RG, Leaf, PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry. 1996;66:17–31.Google Scholar
64.Woodward, SH, Kaloupek, DG, Streeter, CC, et al.Hippocampal volume, PTSD, and alcoholism in combat veterans. Am J Psychiatry. 2006;163:674–681.CrossRefGoogle ScholarPubMed
65.Griebel, G, Stemmelin, J, Gal, CS, Soubrie, P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des. 2005;11:1549–1559.Google Scholar